文献速递头痛与眩晕

瑞美吉泮口崩片急性治疗偏头痛在中国和韩国的安全性与有效性:一项3期双盲随机安慰剂对照试验

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Neurol · 2023-01-01

这项在中国和韩国86家门诊进行的3期双盲随机安慰剂对照试验纳入1431例成人偏头痛患者,按1:1随机接受75 mg瑞美吉泮或安慰剂治疗单次中重度偏头痛发作。服药2小时后,瑞美吉泮组无痛率20% vs 安慰剂组11%,最困扰症状缓解率50% vs 36%,均优于安慰剂;安全性与安慰剂相似。

要点

  • 瑞美吉泮75 mg组服药2小时无痛率20%,安慰剂组11%,风险差9.2(95%CI 5.4-13.0)。
  • 瑞美吉泮组最困扰症状缓解率50%,安慰剂组36%,风险差14.8(95%CI 9.6-20.0)。
  • 最常见不良事件为尿蛋白、恶心和尿路感染,无瑞美吉泮相关严重不良事件。

核心结论

  • 在中国或韩国成人中,单次75 mg瑞美吉泮对急性治疗偏头痛有效,安全性和耐受性与安慰剂相似。
  • 作者认为瑞美吉泮可能成为中国和韩国急性治疗偏头痛药物中的新选择,但需进一步研究支持长期疗效和安全性,并与其它急性治疗药物比较。

研究设计与样本

  • 双盲、随机、安慰剂对照、多中心3期试验,在86家医院和学术医疗中心门诊进行(中国73家,韩国13家)。
  • 纳入≥18岁、偏头痛病史至少1年、筛选前3个月内每月2-8次中重度发作且每月头痛天数少于15天的成人。
  • 按1:1随机分配接受75 mg瑞美吉泮或安慰剂治疗单次中重度偏头痛发作,随机化按预防用药和国家分层。
  • 共随机分配1431例(瑞美吉泮组716例[50%],安慰剂组715例[50%]);瑞美吉泮组668例(93%)和安慰剂组674例(94%)接受治疗;mITT分析纳入1340例(瑞美吉泮组666例[93%],安慰剂组674例[94%])。

主要发现

  • 服药2小时后无痛:瑞美吉泮组132/666例(20%)vs 安慰剂组72/674例(11%),风险差9.2(95%CI 5.4-13.0),p<0.0001。
  • 服药2小时后最困扰症状缓解:瑞美吉泮组336/666例(50%)vs 安慰剂组241/674例(36%),风险差14.8(95%CI 9.6-20.0),p<0.0001。
  • 最常见(≥1%)不良事件:尿蛋白瑞美吉泮组8/668例(1%)vs 安慰剂组7/674例(1%);恶心7/668例(1%)vs 18/674例(3%);尿路感染5/668例(1%)vs 8/674例(1%)。
  • 无瑞美吉泮相关严重不良事件。

临床怎么用

  • 作者认为瑞美吉泮可能成为中国和韩国急性治疗偏头痛药物中的新选择,但需进一步研究支持长期疗效和安全性,并与其它急性治疗药物比较。

局限性

  • 作者指出需进一步研究支持长期疗效和安全性,并与其它急性治疗偏头痛药物比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No acute treatments targeting calcitonin gene-related peptide (CGRP) have been approved for use in China or South Korea. We aimed to compare the efficacy and safety of rimegepant-an orally administered small molecule CGRP antagonist-with placebo in the acute treatment of migraine among adults in these countries. METHODS: This double-blind, randomised, placebo-controlled, multicentre phase 3 trial was done at 86 outpatient clinics at hospitals and academic medical centres (73 in China and 13 in South Korea). Participants were adults (≥18 years) with at least a 1-year history of migraine who had two to eight moderate or severe attacks per month and fewer than 15 headache days per month within the 3 months before the screening visit. Participants were randomly assigned (1:1) to 75 mg rimegepant or placebo to treat a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use of preventive medication and by country. The allocation sequence was generated and implemented by study personnel using an interactive web-response system accessed online from each study centre. All participants, investigators, and the sponsor were masked to treatment assignment. The coprimary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, phonophobia, or photophobia) 2 h after dosing were assessed in the modified intention-to-treat (mITT) population (randomly assigned participants who took study medication for a migraine attack of moderate or severe pain intensity, and provided at least one efficacy datapoint after treatment) using Cochran-Mantel Haenszel tests. Safety was assessed in all participants who received rimegepant or placebo. The study is registered with ClinicalTrials.gov, number NCT04574362, and is completed. FINDINGS: 1431 participants were randomly assigned (716 [50%] to rimegepant and 715 [50%] to placebo). 668 (93%) participants in the rimegepant group and 674 (94%) participants in the placebo group received treatment. 1340 participants were included in the mITT analysis (666 [93%] in the rimegepant group and 674 [94%] in the placebo group). 2 h after dosing, rimegepant was superior to placebo for pain freedom (132 [20%] of 666 vs 72 [11%] of 674, risk difference 9·2, 95% CI 5·4-13·0; p<0·0001) and freedom from the most bothersome symptom (336 [50%] of 666 participants vs 241 [36%] of 674 participants, 14·8, 9·6-20·0; p<0·0001). The most common (≥1%) adverse events were protein in urine (8 [1%] of 668 participants in the rimepegant group vs 7 [1%] of 674 participants in the placebo group), nausea (7 [1%] of 668 vs 18 [3%] of 674), and urinary tract infection (5 [1%] of 668 vs 8 [1%] of 674). There were no rimegepant-related serious adverse events. INTERPRETATION: Among adults living in China or South Korea, a single dose of 75 mg rimegepant was effective for the acute treatment of migraine. Safety and tolerability were similar to placebo. Our findings suggest that rimegepant might be a useful new addition to the range of medications for the acute treatment of migraine in China and South Korea, but further studies are needed to support long-term efficacy and safety and to compare rimegepant with other medications for the acute treatment of migraine in this population. FUNDING: BioShin Limited. TRANSLATIONS: For the Chinese and Korean translations of the abstract see Supplementary Materials section.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Yu S, Kim BK, Guo A, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023. PMID: 37210098. doi:10.1016/S1474-4422(23)00126-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。